Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
53.14
-1.06 (-1.96%)
Mar 3, 2026, 12:38 PM EST - Market open
Spruce Biosciences Employees
Spruce Biosciences had 9 employees as of September 30, 2025. The number of employees decreased by 13 or -59.09% compared to the same quarter last year.
Employees
9
Change
-13
Growth
-59.09%
Revenue / Employee
$77,444
Profits / Employee
-$5,319,889
Market Cap
56.88M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 9 | -13 | -59.09% |
| Jun 30, 2025 | 9 | -13 | -59.09% |
| Mar 31, 2025 | 20 | -2 | -9.09% |
| Dec 31, 2024 | 21 | -8 | -27.59% |
| Sep 30, 2024 | 22 | -9 | -29.03% |
| Jun 30, 2024 | 22 | -10 | -31.25% |
| Mar 31, 2024 | 22 | -8 | -26.67% |
| Dec 31, 2023 | 29 | 2 | 7.41% |
| Sep 30, 2023 | 31 | 9 | 40.91% |
| Jun 30, 2023 | 32 | 15 | 88.24% |
| Mar 31, 2023 | 30 | 14 | 87.50% |
| Dec 31, 2022 | 27 | 12 | 80.00% |
| Sep 30, 2022 | 22 | 3 | 15.79% |
| Jun 30, 2022 | 17 | -4 | -19.05% |
| Mar 31, 2022 | 16 | -3 | -15.79% |
| Dec 31, 2021 | 15 | -2 | -11.76% |
| Sep 30, 2021 | 19 | 4 | 26.67% |
| Jun 30, 2021 | 21 | 6 | 40.00% |
| Mar 31, 2021 | 19 | 4 | 26.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 148 |
| Metagenomi Therapeutics | 124 |
| ImmuCell | 84 |
| InflaRx | 74 |
| Rallybio | 15 |
| Instil Bio | 14 |
| MAIA Biotechnology | 13 |
| Alterity Therapeutics | 9 |
SPRB News
- 21 hours ago - Spruce Biosciences to Present at Upcoming Investor Conferences in March - Business Wire
- 13 days ago - Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
- 13 days ago - Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Business Wire
- 25 days ago - Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
- 4 weeks ago - Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team - Business Wire
- 4 weeks ago - Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™ - Business Wire
- 6 weeks ago - Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration - PRNewsWire
- 7 weeks ago - Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital - Business Wire